MicuRx Pharmaceuticals, Cumencor Pharmaceuticals Partner with Pfizer to Discover and Develop Antibiotics for Drug-Resistant TB

摘要

MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc. announced that the companies have entered a collaboration with Pfizer (NYSE: PFE) to discover novel therapeutic agents to treat multidrug resistant tuberculosis (MDR-TB). Cumencor Pharmaceuticals is a China-based biotechnology company applying MicuRx's proprietary technology platform to discover and develop novel antibiotics for MDR-TB.